DURECT Corporation (NASDAQ:DRRX) has scheduled a conference call for 2nd November 2020 at 4:30 PM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.durect.com
Earnings Expectation
DURECT Corporation biopharmaceutical researcher, is reporting third quarter earnings results on Monday 2nd November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.04 per share from $ 3.56 million in revenue. For the full year, analysts predict revenues of $ 36.22 million, while looking forward to loss of $ 0.06 per share.
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival.
